De fase 3-effectiviteitsstudie met 40.805 deelnemers uit 11 landen toonde sterke relatieve werkzaamheid voor alle griepstammen in het vaccin: 29,6% voor A/H1N1, 22,2% voor A/H3N2 en 29,1% voor ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

William Blair merkte op dat elk component van Moderna’s combinatievaccin mRNA-1083 nu positieve fase III-data heeft bereikt ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

See the latest Moderna stock price and MRNA stock rating, ... Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.